Advanced search
1 file | 628.32 KB Add to list

The effect of docetaxel on developing oedema in patients with breast cancer : a systematic review

Author
Organization
Abstract
Docetaxel is extensively used in chemotherapy for the treatment of breast cancer. Little attention has been given to oedema as a possible side effect of docetaxel-containing therapies. Until now, no review was conducted to evaluate docetaxel-containing therapies versus docetaxel-free therapies on the magnitude of the risk of developing oedema. In this systematic review, we investigated the risk of developing oedema in patients being treated for breast cancer with or without docetaxel. In this systematic literature review, we searched PubMed and Web of Knowledge for studies on breast cancer patients treated with chemotherapy containing docetaxel. We included clinical trials comparing docetaxel versus docetaxel-free chemotherapy. Oedema had to be reported and measured as a key outcome or an adverse effect. Methodological checklists were used to assess the risk of bias within the selected studies. Seven randomised clinical trials were included. Six trials were of moderate methodological quality. All trials showed an increased rate of oedema in the docetaxel- treatment arm. The trial of weakest methodological quality reported the highest incidence of oedema. The results moderately suggest that adjuvant chemotherapy containing docetaxel is related to a significantly increased risk of developing oedema, compared with docetaxel-free chemotherapy.
Keywords
taxotere, chemotherapy, mamma carcinoma, risk, RANDOMIZED PHASE-III, FLUID RETENTION, CHEMOTHERAPY, ADJUVANT, TRIAL, EPIRUBICIN

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 628.32 KB

Citation

Please use this url to cite or link to this publication:

MLA
Hugenholtz-Wamsteker, Willemijn et al. “The Effect of Docetaxel on Developing Oedema in Patients with Breast Cancer : a Systematic Review.” EUROPEAN JOURNAL OF CANCER CARE 25.2 (2016): 269–279. Print.
APA
Hugenholtz-Wamsteker, W., Robbeson, C., Nijs, J., Hoelen, W., & Meeus, M. (2016). The effect of docetaxel on developing oedema in patients with breast cancer : a systematic review. EUROPEAN JOURNAL OF CANCER CARE, 25(2), 269–279.
Chicago author-date
Hugenholtz-Wamsteker, Willemijn, Conny Robbeson, Jo Nijs, Wouter Hoelen, and Mira Meeus. 2016. “The Effect of Docetaxel on Developing Oedema in Patients with Breast Cancer : a Systematic Review.” European Journal of Cancer Care 25 (2): 269–279.
Chicago author-date (all authors)
Hugenholtz-Wamsteker, Willemijn, Conny Robbeson, Jo Nijs, Wouter Hoelen, and Mira Meeus. 2016. “The Effect of Docetaxel on Developing Oedema in Patients with Breast Cancer : a Systematic Review.” European Journal of Cancer Care 25 (2): 269–279.
Vancouver
1.
Hugenholtz-Wamsteker W, Robbeson C, Nijs J, Hoelen W, Meeus M. The effect of docetaxel on developing oedema in patients with breast cancer : a systematic review. EUROPEAN JOURNAL OF CANCER CARE. 2016;25(2):269–79.
IEEE
[1]
W. Hugenholtz-Wamsteker, C. Robbeson, J. Nijs, W. Hoelen, and M. Meeus, “The effect of docetaxel on developing oedema in patients with breast cancer : a systematic review,” EUROPEAN JOURNAL OF CANCER CARE, vol. 25, no. 2, pp. 269–279, 2016.
@article{7106531,
  abstract     = {Docetaxel is extensively used in chemotherapy for the treatment of breast cancer. Little attention has been given to oedema as a possible side effect of docetaxel-containing therapies. Until now, no review was conducted to evaluate docetaxel-containing therapies versus docetaxel-free therapies on the magnitude of the risk of developing oedema. In this systematic review, we investigated the risk of developing oedema in patients being treated for breast cancer with or without docetaxel. In this systematic literature review, we searched PubMed and Web of Knowledge for studies on breast cancer patients treated with chemotherapy containing docetaxel. We included clinical trials comparing docetaxel versus docetaxel-free chemotherapy. Oedema had to be reported and measured as a key outcome or an adverse effect. Methodological checklists were used to assess the risk of bias within the selected studies. Seven randomised clinical trials were included. Six trials were of moderate methodological quality. All trials showed an increased rate of oedema in the docetaxel- treatment arm. The trial of weakest methodological quality reported the highest incidence of oedema. The results moderately suggest that adjuvant chemotherapy containing docetaxel is related to a significantly increased risk of developing oedema, compared with docetaxel-free chemotherapy.},
  author       = {Hugenholtz-Wamsteker, Willemijn and Robbeson, Conny and Nijs, Jo and Hoelen, Wouter and Meeus, Mira},
  issn         = {0961-5423},
  journal      = {EUROPEAN JOURNAL OF CANCER CARE},
  keywords     = {taxotere,chemotherapy,mamma carcinoma,risk,RANDOMIZED PHASE-III,FLUID RETENTION,CHEMOTHERAPY,ADJUVANT,TRIAL,EPIRUBICIN},
  language     = {eng},
  number       = {2},
  pages        = {269--279},
  title        = {The effect of docetaxel on developing oedema in patients with breast cancer : a systematic review},
  url          = {http://dx.doi.org/10.1111/ecc.12261},
  volume       = {25},
  year         = {2016},
}

Altmetric
View in Altmetric
Web of Science
Times cited: